Table III.

Cumulative Incidence of Grade II–IV and III–IV acute GVHD at Day 100, and 1-Year NRM in Matched Siblings who received PB versus BM and Matched Unrelated Donors who did or did not receive ATG^*.

N=44*	%Cumulative Incidence	Hazard Ratio (95% CI)	p-value
Acute GVHD II–IV
MRD PB (n=9)	56% (31–100)	1.1 (0.2–5.9)	0.9
MRD BM (n=5)	40% (14–100)	Ref.
Acute GVHD III–IV
MRD PB	11% (2–70)	N/E	0.5
MRD BM	0%
Acute GVHD II–IV
MUD BM ATG (n=20)	36% (21–68)	Ref.
MUD BM No ATG (n=10)	80% (59–100)	2.8 (1.1–7.5)	0.03
Acute GVHD III–IV
MUD BM ATG (n=20)	10% (3–41)	Ref.
MUD BM No ATG (n=10)	50% (27–93)	3.1 (0.8–11)	0.1
NRM 1-year
MUD BM ATG (n=20)	25% (12–53)	0.4	0.25
MUD BM No ATG (n=10)	40% (19–85)	Ref.

^*3 patients who experienced primary graft failure were removed from the analysis, 2 MUD BM recipients and 1 MRD BM recipient. 2 MUD patients who received PB and ATG were removed from the analysis of the effect of ATG.